LYEL

In the past six months, Lyell Immunopharma, Inc.'s stock price has been impacted by earnings reports, clinical trial progress, financing activities, analyst ratings and insider trading, and overall stock performance. Lyell reported its Q4 and full-year 2025 financial results on March 12, 2026, and its Q1 2026 financial results on May 6, 2026. The company has announced significant progress in its clinical pipeline, including the commencement of patient dosing in the PiNACLE-H2H Phase 3 trial for ronde-cel and continued dosing for LYL273. In March 2026, Lyell closed the second $50 million tranche of a $100 million equity private placement from July 2025, following the achievement of a clinical milestone. Analyst ratings for LYEL have been mixed, ranging from "Strong Buy" to "Sell" recommendations, with an average rating of "Moderate Buy" and an average price target of $43.00 as of May 10, 2026. As of April 22, 2026, the share price was $24.78, representing a significant increase from $9.56 on April 23, 2025.